Royal London Asset Management Ltd. Buys 4,307 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Royal London Asset Management Ltd. increased its position in Royalty Pharma plc (NASDAQ:RPRX) by 2.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 160,184 shares of the biopharmaceutical company’s stock after purchasing an additional 4,307 shares during the quarter. Royal London Asset Management Ltd.’s holdings in Royalty Pharma were worth $4,532,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Blue Trust Inc. grew its holdings in Royalty Pharma by 362.7% during the 3rd quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 943 shares during the last quarter. Gladius Capital Management LP acquired a new stake in shares of Royalty Pharma during the 2nd quarter worth approximately $32,000. EverSource Wealth Advisors LLC raised its position in shares of Royalty Pharma by 32.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 655 shares during the last quarter. Transamerica Financial Advisors Inc. increased its holdings in Royalty Pharma by 99.9% in the third quarter. Transamerica Financial Advisors Inc. now owns 3,459 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 1,729 shares during the last quarter. Finally, iA Global Asset Management Inc. raised its position in shares of Royalty Pharma by 274.7% in the 2nd quarter. iA Global Asset Management Inc. now owns 6,388 shares of the biopharmaceutical company’s stock valued at $168,000 after acquiring an additional 4,683 shares during the period. 54.35% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently commented on RPRX shares. StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. The Goldman Sachs Group lifted their target price on Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Finally, Citigroup decreased their price target on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $41.67.

Royalty Pharma Price Performance

Shares of NASDAQ RPRX opened at $25.91 on Monday. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.64. Royalty Pharma plc has a 1-year low of $25.10 and a 1-year high of $31.66. The firm’s 50-day moving average price is $26.98 and its 200-day moving average price is $27.28. The firm has a market capitalization of $15.27 billion, a P/E ratio of 13.42, a P/E/G ratio of 4.59 and a beta of 0.46.

Royalty Pharma Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be given a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a yield of 3.24%. The ex-dividend date is Friday, November 15th. Royalty Pharma’s payout ratio is 43.52%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.